(ROIV) Roivant Sciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 22.412m USD | Total Return: 173.9% in 12m
Avg Turnover: 145M
Qual. Beats: 0
Rev. Trend: -97.4%
Qual. Beats: 0
Warnings
High Debt while negative Cash Flow
Tailwinds
Leader, Tailwind, Pullback 52w
Roivant Sciences Ltd. is a London-based clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and cardiopulmonary diseases. The company utilizes a Vant business model, where it creates subsidiary companies to focus on specific therapeutic areas or technologies, a strategy designed to diversify risk while maintaining operational agility. Its current pipeline includes monoclonal antibodies like IMVT-1402 and batoclimab, small molecule inhibitors such as brepocitinib, and the inhaled sGC activator mosliciguat.
The company also maintains proprietary delivery platforms, specifically lipid nanoparticle (LNP) and ligand conjugate systems. In the biotechnology sector, these platforms are critical for the targeted delivery of genetic medicines and complex proteins. Investors may find it useful to examine ValueRay for deeper insights into the companys valuation and pipeline potential. Roivant’s focus remains on high-unmet-need indications, including Graves disease, dermatomyositis, and pulmonary hypertension.
- IMVT-1402 clinical trial data readouts drive long-term valuation in autoimmune markets
- Brepocitinib Phase 3 results for dermatomyositis determine near-term regulatory approval prospects
- Strategic divestitures and licensing deals provide significant non-dilutive capital reserves
- Mosliciguat clinical advancement dictates entry into the multi-billion dollar pulmonary market
- Research and development expenses for clinical-stage pipeline impact quarterly cash burn rates
| Net Income: -299.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA 2.24 > 1.0 |
| NWC/Revenue: 48.6k% < 20% (prev 16.7k%; Δ 31.9k% < -1%) |
| CFO/TA -0.13 > 3% & CFO -750.3m > Net Income -299.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (693.9m) vs 12m ago -1.90% < -2% |
| Gross Margin: 84.44% > 18% (prev 0.97%; Δ 8.35k% > 0.5%) |
| Asset Turnover: 0.15% > 50% (prev 0.53%; Δ -0.39% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.70 (Total Current Assets 4.29b - Total Current Liabilities 281.2m) / Total Assets 5.71b |
| B: -0.09 (Retained Earnings -501.8m / Total Assets 5.71b) |
| C: -0.09 (EBIT TTM -515.1m / Avg Total Assets 5.57b) |
| D: -1.20 (Book Value of Equity -497.5m / Total Liabilities 416.3m) |
| Altman-Z'' = 2.45 = A |
As of May 24, 2026, the stock is trading at USD 30.88 with a total of 9,682,904 shares traded.
Over the past week, the price has changed by +2.29%,
over one month by +2.78%,
over three months by +7.93% and
over the past year by +173.86%.
Roivant Sciences has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ROIV.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 36.1 | 17% |
P/B = 5.149
Revenue TTM = 8.26m USD
EBIT TTM = -515.1m USD
EBITDA TTM = -490.8m USD
Long Term Debt = unknown (none)
Short Term Debt = 11.1m USD (from shortTermDebt, last fiscal year)
Debt = 107.4m USD (from shortLongTermDebtTotal, last fiscal year) (leases 108.9m already included)
Net Debt = -4.18b USD (calculated: Debt 107.4m - CCE 4.29b)
Enterprise Value = 18.2b USD (22.4b + Debt 107.4m - CCE 4.29b)
Interest Coverage Ratio = unknown (Ebit TTM -515.1m / Interest Expense TTM 0.0)
EV/FCF = -24.03x (Enterprise Value 18.2b / FCF TTM -758.6m)
FCF Yield = -4.16% (FCF TTM -758.6m / Enterprise Value 18.2b)
FCF Margin = -9.18k% (FCF TTM -758.6m / Revenue TTM 8.26m)
Net Margin = -3.63k% (Net Income TTM -299.8m / Revenue TTM 8.26m)
Gross Margin = 84.44% ((Revenue TTM 8.26m - Cost of Revenue TTM 1.28m) / Revenue TTM)
Gross Margin QoQ = 87.30% (prev 64.98%)
Tobins Q-Ratio = 3.19 (Enterprise Value 18.2b / Total Assets 5.71b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 107.4m)
Taxrate = 21.66% (98.4m / 454.1m)
NOPAT = -403.5m (EBIT -515.1m * (1 - 21.66%)) [loss with tax shield]
Current Ratio = 15.26 (Total Current Assets 4.29b / Total Current Liabilities 281.2m)
Debt / Equity = 0.02 (Debt 107.4m / totalStockholderEquity, last quarter 5.29b)
Debt / EBITDA = 8.53 (negative EBITDA) (Net Debt -4.18b / EBITDA -490.8m)
Debt / FCF = 5.52 (negative FCF - burning cash) (Net Debt -4.18b / FCF TTM -758.6m)
Total Stockholder Equity = 4.57b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.38% (Net Income -299.8m / Total Assets 5.71b)
RoE = -6.56% (Net Income TTM -299.8m / Total Stockholder Equity 4.57b)
RoCE = -9.49% (EBIT -515.1m / Capital Employed (Total Assets 5.71b - Current Liab 281.2m))
RoIC = -7.48% (negative operating profit) (NOPAT -403.5m / Invested Capital 5.40b)
WACC = 8.43% (E(22.4b)/V(22.5b) * Re(8.47%) + D(107.4m)/V(22.5b) * Rd(0.0%) * (1-Tc(0.22)))
Discount Rate = 8.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -77.78 | Cagr: -8.36%
[DCF] Fair Price = unknown (Cash Flow -758.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.22 | # QB: 0
Revenue Correlation: -97.40 | Revenue CAGR: -52.23% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.33 | Chg30d=-14.96% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.38 | Chg30d=-15.04% | Revisions=+33% | Analysts=3
EPS current Year (2027-03-31): EPS=-1.16 | Chg30d=-12.33% | Revisions=+14% | GrowthEPS=-7.5% | GrowthRev=+764.8%
EPS next Year (2028-03-31): EPS=-1.30 | Chg30d=-42.49% | Revisions=-43% | GrowthEPS=-11.8% | GrowthRev=+553.3%
[Analyst] Revisions Ratio: -43%